EDITORIAL SECTIONS

Divya Mishra is a board certified oncologist with over 17 years’ experience in the pharmaceutical/CRO industry, clinical practice, and academia, in areas of oncology/haematology, family medicine, palliative medicine, and outcomes research. Mishra has worked across multiple geographies and diverse, multicultural settings for organisations such as Pfizer, IQVIA, and SFJ. She is currently working at ICON as a medical director and therapeutic expert for the oncology/haematology disease areas in the APAC region, based in the regional headquarters in Singapore.

Pooja is a Healthcare & Life Sciences leader at Thoughtworks with over 15 years of experience in technology consulting. Specialising in AI-driven solutions and strategic initiatives that enhance drug discovery and patient care, she has a unique background in both bioinformatics and product management. Passionate about navigating ambiguity and solving customer problems, Pooja’s current focus is on leveraging emerging technologies to accelerate innovation in healthcare and life sciences.

Associate Professor Dr. Oon Chern Ein is dedicated to advancing innovative cancer therapies. She earned her BSc (First Class Hons) in Biotechnology from Universiti Kebangsaan Malaysia and pursued her DPhil in Medical Oncology at the University of Oxford, United Kingdom. Following this, she trained as a postdoctoral fellow at Karolinska Institutet, Sweden. She has served as a lecturer at Universiti Sains Malaysia since 2013. Chern’s work in molecular therapeutics has earned her numerous prestigious awards, including the L’Oreal-UNESCO For Women in Science National Fellowship (2015), the Women of the Future Awards (South East Asia), and the Malaysian National Young Scientist Award (2018). She was further recognized with the Promising Academician Award and Excellent Service Award by the Malaysian Ministry of Higher Education (2019), alongside the British Council Study UK Alumni Award (Professional Achievement Category) and MINDS Women Scientist Award in 2020. Most recently, she received the Singapore Academies-ASEAN Fellowship from the Singapore National Research Foundation to train in drug discovery at A*STAR Singapore to strengthen her industrial insights. Her multidisciplinary research encompasses drug discovery, cancer-targeted therapies, and bioengineering solutions through collaborations with industry partners. She holds two granted patents in Malaysia (MY-203445-A, MY-199524-A) for small molecule inhibitors targeting anti-cancer and anti-angiogenesis pathways. As a member of the Global Young Academy, Chern actively champions female empowerment and education for all. Chern’s research continues to bridge academia and industry, striving to transform cancer therapy through novel therapeutic strategies.

Victor H. Bustos, Ph.D., is the Vice President of Preclinical R&D at Ordaos Bio. A specialist in protein engineering with a doctorate in Biomedicine, he leads the design of AI-generated mini-proteins. Previously, he spent 17 years at Rockefeller University focusing on complex cellular mechanisms and therapeutic target validation.

Alena Romanova is a Scientist I at Ordaos Bio, where she develops experimental workflows for protein characterisation and biologics discovery, including the application of cell-free protein expression and biochemical assays.

Dr Deepika Arora is an accomplished professional with expertise in project management, process improvement, and operational excellence. She brings strong scientific expertise and experience in prolific biologics, contributing to innovation and quality-driven outcomes. With a commitment to continuous learning, she has led cross-functional initiatives across diverse industries and writes on leadership, strategy, and professional development.

Aditya Banerjee is a senior scientist specialising in stem cell biology, regenerative medicine, and translational research. His work focuses on GMP-compliant cell therapy manufacturing, exosome research, and quality systems. Passionate about advancing scientific innovation, he writes on emerging biotechnologies, laboratory excellence, and their translation into meaningful clinical applications.